The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Dudchenko N.G.

Russian Academy for Continuing Professional Education, Moscow, Russia

Vasenina E.E.

Rossiĭskaia meditsinskaia akademiia poslediplomnogo obrazovaniia, Moskva

Rapidly progressive dementia

Authors:

Dudchenko N.G., Vasenina E.E.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(9‑2): 78‑84

DOI: 10.17116/jnevro201911909278

Read: 32855 times

Download PDF (RU)
Contact the author
Table of contents

RAPIDLY PROGRESSIVE DEMENTIA
RAPIDLY PROGRESSIVE DEMENTIA

To cite this article:

Dudchenko NG, Vasenina EE. Rapidly progressive dementia. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(9‑2):78‑84. (In Russ.)
https://doi.org/10.17116/jnevro201911909278

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Animal expe­rimental models in the study of age-dependent cere­bral microangiopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):57-68
Cyto­kine status of patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):5-12
The main mechanisms of deve­lopment of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18
Curcumin-induced increased reti­nal fluorescence as a new method in the early diagnosis of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):19-25
Differential diagnosis of Alzheimer’s disease and vascular cognitive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):26-35
A comprehensive study of Alzheimer’s disease biomarkers in plasma and cere­brospinal fluid. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):43-53
Prospects for treating Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):54-60
Pathogenetic aspe­cts of autoantibody formation to central nervous system stru­ctures in patients with ence­phalitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):53-58
Treatment features of patients with vascular cognitive impairments. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):69-76
Novel prospects for early diagnosis of cognitive impairment using Eye-tracking technology. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):13-20
Abstract:

Accurate establishment of the etiology of rapidly progressive dementia is a difficult but very important task, since a number of diseases and conditions that can cause cognitive decline are potentially curable and can be completely reversible with proper diagnosis and timely treatment. While a delay in treatment can lead to severe residual deficiency or death. The article provides current data on the etiology, pathogenesis, clinical presentations, diagnosis and treatment of major diseases and pathological conditions that may cause rapidly progressive dementia.

Keywords:

dementia
prion diseases
Jakob-Creutzfeldt disease
Alzheimer disease
vascular dementia
autoimmune encephalitis
infection dementia
brain tumor-associated dementia
toxic and metabolic dementias

Authors:

Dudchenko N.G.

Russian Academy for Continuing Professional Education, Moscow, Russia

Vasenina E.E.

Rossiĭskaia meditsinskaia akademiia poslediplomnogo obrazovaniia, Moskva

Close metadata

References:

  1. Levin OS. Diagnosis and treatment of dementia in clinical practice. M: MEDpress-inform; 2010. https://doi.org/10.17116/jnevro20151156217-25
  2. Heinemann U, GawineckaJ, Schmidt C, Zerr I. Differential diagnosis of rapid progressive dementia. Eur Neurol Rev. 2010;5(2):21-28.
  3. Geschwind MD, Haman A, Miller BL. Rapidly Progressive Dementia. Neurologic Clinics. 2007;25(3):783-807. https://doi.org/10.1016/j.ncl.2007.04.001
  4. Schmidt C. Rapidly Progressive Alzheimer Disease. Archives of Neurology. 2011;68(9):1124. https://doi.org/10.1001/archneurol.2011.189
  5. Studart NA, Soares NHR, Simabukuro MM, Solla DJF, Gonçalves MRR, Fortini I, Nitrini R. Rapidly Progressive Dementia. Alzheimer Disease & Associated Disorders. 2017;31(3):239-243. https://doi.org/10.1097/wad.0000000000000170
  6. Anuja P, Venugopalan V, Darakhshan N, Awadh P, Wilson V, Manoj G, Manish M, Vivek L. Rapidly progressive dementia: An eight year (2008—2016) retrospective study. PLoS One. 2018;13(1):e0189832. https://doi.org/10.1371/journal.pone.0189832
  7. Papageorgiou SG, Kontaxis T, Bonakis A, Karahalios G, Kalfakis N, Vassilopoulos D. Rapidly Progressive Dementia. Alzheimer Disease & Associated Disorders. 2009;23(4):337-346. https://doi.org/10.1097/wad.0b013e31819e099b
  8. Ladogana A, Puopolo M, Croes EA, Budka H, Jarius C, Collins S, Zerr I. Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology. 2005;64(9):1586-1591. https://doi.org/10.1212/01.wnl.0000160117.56690.b2
  9. Zerr I, Kallenberg K, Summers DM, Romero C, Taratuto A, Heinemann U, Sanchez-Juan P. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain. 2009;132(10):2659-2668. https://doi.org/10.1093/brain/awp191
  10. Ludewigs H, Zuber C, Vana K, Nikles D, Zerr I, Weiss S. Therapeutic approaches for prion disorders. Expert Review of Anti-Infective Therapy. 2007;5(4):613-630. https://doi.org/10.1586/14787210.5.4.613
  11. Kovacs G, Budka H. Molecular Pathology of Human Prion Diseases. International Journal of Molecular Sciences. 2009;10(3):976-999. https://doi.org/10.3390/ijms10030976
  12. Vitali P, Maccagnano E, Caverzasi E, Henry RG, Haman A, Torres-Chae C, Johnson DY, Miller BL, Geschwind MD. Diffusion-weighted MRI hyperintensity patterns differentiate CJD from other rapid dementias. Neurology. 2011;76(20):1711-1719. https://doi.org/10.1212/wnl.0b013e31821a4439
  13. Collins SJ. Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. Brain. 2006;129(9):2278-2287. https://doi.org/10.1093/brain/awl159
  14. Chitravas N, Jung RS, Kofskey DM, Blevins JE, Gambetti P, Leigh RJ, Cohen ML. Treatable neurological disorders misdiagnosed as Creutzfeldt-Jakob disease. Annals of Neurology. 2011;70(3):437-444. https://doi.org/10.1002/ana.22454
  15. Varges D, Manthey H, Heinemann U, Ponto C, Schmitz M, Schulz-Schaeffer WJ, Krasnianski A, Breithaupt M, Fincke F, Kramer K, Friede T, Zerr I. Doxycycline in early CJD: a double-blinded randomised phase II and observational study. Journal of Neurology, Neurosurgery & Psychiatry. 2016;88(2):119-125. https://doi.org/10.1136/jnnp-2016-313541
  16. Chitravas N, Jung RS, Kofskey DM, Blevins JE, Gambetti P, Leigh RJ, Cohen ML. Treatable neurological disorders misdiagnosed as Creutzfeldt-Jakob disease. Annals of Neurology. 2011;70(3):437-444. https://doi.org/10.1002/ana.22454
  17. Sano K, Satoh KK, Atarashi R, Takashima H, Schmitz M, Zerr I. Early detection of abnormal prion protein in genetic human prion diseases now possible using real-time QUICassay. PLoS One. 2013;8(1):e54915. https://doi.org/10.3233/jad-171181
  18. Abu-Rumeileh S, Capellari S, Parchi P. Rapidly Progressive Alzheimer’s disease: contributions to clinical-pathological definition and diagnosis. Journal of Alzheimer’s Disease. 2018;63(3):887-897. https://doi.org/10.3233/jad-171181
  19. Hecht M, Krämer LM, von Arnim CAF, Otto M, Thal DR. Capillary cerebral amyloid angiopathy in Alzheimer’s disease: association with allocortical/hippocampal microinfarcts and cognitive decline. Acta Neuropathologica. 2018;135(5):681-694. https://doi.org/10.1007/s00401-018-1834-y
  20. Kumar A, Singh A. A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacological Reports. 2015;67(2):195-203.
  21. Karch CM, Goate AM. Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biological Psychiatry. 2015;77(1):43-51.
  22. Cramm M, Schmitz M, Karch A, Mitrova E, Kuhn F, Schroede B, Zerr I. Stability and Reproducibility Underscore Utility of RT-QuIC for Diagnosis of Creutzfeldt-Jakob Disease. Molecular Neurobiology. 2015;53(3):1896-1904. https://doi.org/10.1007/s12035-015-9133-2
  23. Will R, Mackenzie G. Creutzfeldt-Jakob disease: recent developments. F1000Res. 2017;6:2053. https://doi.org/10.12688/f1000research.12681.1
  24. Levin OS, Vasenina EE. 25 Twenty-five years of the amyloid hypothesis of Alzheimer’s disease: advances, failures and new perspectives Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2016;116(6):3-9. (In Russ.) https://doi.org/10.17116/jnevro2016116623-9
  25. Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Elliott CL, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Ryan LM, Scheltens P, Siemers E, Silverberg N, Snyder HM, Sperling R. 2017 NIA-AA Research framework to investigate the Alzheimer’s disease Continuum. Alzheimer’s Dementia. 2017;13(7):890-891. https://doi.org/10.1016/j.jalz.2017.07.294
  26. Schmidt C, Redyk K, Meissner B, KrackL, von Ahsen N, Roeber S, Zerr I. Clinical features of rapidly progressive Alzheimer’s disease. Dementia and Geriatric Cognitive Disorders. 2010;29(4):371-378. https://doi.org/10.1159/000278692
  27. Poliakova T, Levin O, Arablinskiy A, Vasenina E, Zerr I. Cerebral microbleeds in early Alzheimer’s disease. Journal of Neurology. 2016;263(10):1961-1968. https://doi.org/10.1007/s00415-016-8220-2
  28. Jack CR. Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. Radiology. 2012;263(2):344-361. https://doi.org/10.1148/radiol.12110433
  29. Graham WV, Bonito-Oliva A, Sakmar TP. Update on Alzheimer’s disease therapy and prevention strategies. Annual Review of Medicine. 2017;68:413-430. https://doi.org/10.1146/annurev-med-042915-103753
  30. Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, Jeffreys M, Hyde C.The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of Technology Appraisal No. 111): a systematic review and economic model. Health Technology Assessment. 2012;16(21):1-470. https://doi.org/10.3310/hta16210
  31. Jellinger KA, Attems J. The impact of vascular and Alzheimer pathologies in Lewy body disease. Alzheimer’s Dementia. 2009;5(4):163-164. https://doi.org/10.1016/j.jalz.2009.05.563
  32. Wang G, Cui H, Huang Y. Reader response: Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2018;90(6):1-300. https://doi.org/10.1212/wnl.0000000000004918
  33. Graff-Radford J, Aakre J, Savica R, Boeve B, Kremers WK, Ferman TJ, Jones DT, Kantarci K, Knopman DS, Dickson DW, Kukull WA, Petersen RC. Duration and pathologic correlates of Lewy body disease. JAMA Neurology. 2017;74(3):310-315. https://doi.org/10.1001/jamaneurol.2016.4926
  34. Abu-Rumeileh S, Capellari S, Parchi P. Rapidly progressive Alzheimer’s disease: contributions to clinical-pathological definition and diagnosis. Journal of Alzheimer’s Disease. 2018;63(3):887-897. https://doi.org/10.3233/jad-171181
  35. Gaig C, Valldeoriola F, Gelpi E, Ezquerra M, Llufriu S, Buongiorno M, Tolosa E. Rapidly progressive diffuse Lewy body disease. Movement Disorders. 2011;26(7):1316-1323. https://doi.org/10.1002/mds.23506
  36. Garcia-Esparcia P, López-González I, Grau-Rivera O, García-Garrido MF, Konetti A, LlorensF, Zafar S, Carmona M, del Rio JA, Zerr I, Gelp E, Ferrer I. Dementia with Lewy bodies: molecular pathology in the frontal cortex in typical and rapidly progressive forms. Frontiers in Neurology. 2017;8. https://doi.org/10.3389/fneur.2017.00089
  37. Levin OS, Vasenina EE, Chimagomedova ASh, Dudchenko NG. Dementiawith Lewibodyes. Review of psychiatry and medical psychology named after V.M. Bekhterev. 2018;2:11-21.
  38. Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev. 2012;3:CD006504.
  39. Mori E, Ikeda M, Kosaka K. Donepezil for dementia with Lewy bodies: A randomized, placebo-controlled trial. Annals of Neurology. 2012;72(1):41-52. https://doi.org/10.1002/ana.23557
  40. Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, Leroi I, Pozo-Rodriguez F, Minthon L, Londos E. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613-618. https://doi.org/10.1016/S1474-4422(09)70146-2
  41. Weintraub D, Hurtig HI. Presentation and Management of Psychosis in Parkinson’s Disease and Dementia With Lewy Bodies. American Journal of Psychiatry. 2007;164(10):1491-1498. https://doi.org/10.1176/appi.ajp.2007.07040715
  42. Sachdev P, Kalaria R, O’Brien J, Skoog I, Alladi S, Black SE, Blacker D, Blazer DG, Chen C, Chui H, Ganguli M, Jellinger K, Jeste DV, Pasquier F, Paulsen J, Prins N, Rockwood K, Roman G, Scheltens P; Internationlal Society for Vascular Behavioral and Cognitive Disorders. Diagnostic Criteria for Vascular Cognitive Disorders. Alzheimer Disease Associated Disorders. 2014;28(3):206-218. https://doi.org/10.1097/wad.0000000000000034
  43. Geschwind MD, Shu H, Haman A, Sejvar JJ, Miller BL. Rapidly progressive dementia. Annals of Neurology. 2008;64(1):97-108. https://doi.org/10.1002/ana.21430
  44. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):1197-2204. https://doi.org/10.1212/01.wnl.0000271090.28148.24
  45. Vilela P. Acute stroke differential diagnosis: Stroke mimics. European Journal of Radiology. 2017;96:133-144. https://doi.org/10.1016/j.ejrad.2017.05.008
  46. Salvarani C, Brown RD Jr, Calamia KT, Christianson TJ, Weigand SD, Miller DV, Giannini C, Meschia JF, Huston J 3rd, Hunder GG. Primary central nervous system vasculitis: analysis of 101 patients. Annals of Neurology. 2007;62(5):442-451. https://doi.org/10.1002/ana.21226
  47. Salvarani C, Brown RD, Christianson T, Miller DV, Giannini C, Huston J, Hunder GG. An Update of the mayo clinic cohort of patients with adult primary central nervous system vasculitis. Medicine. 2015;94(21):e738. https://doi.org/10.1097/md.0000000000000738
  48. Liu XY, Gonzalez-Toledo ME, Fagan A, Duan WM, Liu Y, Zhang S, Li B, Piao CS, Nelson L, Zhao LR. Novel pathological features and potential therapeutic approaches for CADASIL: insights obtained from a mouse model of CADASIL. Smart Science and Technology, LLC: Therapeutic Targets for Neurological Diseases; 2015. https://doi.org/10.14800/ttnd.434
  49. Hermann P, Laux M, Glatzel M, Matschke J, Knipper T, Goebel S, Treig J, Schulz-Schaeffer W, Cramm M, Schmitz M, Zerr I. Validation and utilization of amended diagnostic criteria in Creutzfeldt-Jakob disease surveillance. Neurology. 2018;91(4):331-338. https://doi.org/10.1212/wnl.0000000000005860
  50. Pasi M, Nappini S, Salvadori E, Mangiafico S, Limbucci N, Pantoni L. Rapidly progressive cognitive impairment in a patient with high flow dural arteriovenous fistulas, cerebral sinus thrombosis and protein S deficiency. Journal of Clinical Neuroscience. 2014;21(9):1654-1656. https://doi.org/10.1016/j.jocn.2013.12.025
  51. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. The Lancet Neurology. 2007;6(9):782-792. https://doi.org/10.1016/s1474-4422(07)70195-3
  52. Granerod J, Ambrose HE, Davies NW, Clewley JP, Walsh AL, Morgan D, Cunningham R, Zuckerman M, Mutton KJ, Solomon T, Ward KN, Lunn MP, Irani SR, Vincent A, Brown DW, Crowcroft NS. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. The Lancet Infectious Diseases. 2010;10(12):835-844. https://doi.org/10.1016/s1473-3099(10)70222-x
  53. Gelfand JM. Autoimmune encephalitis after herpes simplex encephalitis: insights into pathogenesis. The Lancet Neurology. 2018;17(9):733-735. https://doi.org/10.1016/s1474-4422(18)30279-5
  54. Dalmau J, Graus F. Antibody-Mediated Encephalitis. New England Journal of Medicine. 2018;378(9):840-851. https://doi.org/10.1056/nejmra1708712
  55. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. The Lancet Neurology. 2011;10(1):63-74. https://doi.org/10.1016/s1474-4422(10)70253-2
  56. Tüzün E, Zhou L, Baehring JM, Bannykh S, Rosenfeld MR, Dalmau J. Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. Acta Neuropathologica. 2009;118(6):737-743. https://doi.org/10.1007/s00401-009-0582-4
  57. Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, Friese MA, Galea I, Kullmann DM, Beeson D, Lang B, Bien CG, Vincent A.N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain. 2010;133(6):1655-1667. https://doi.org/10.1093/brain/awq113
  58. Vasenina EE, Levin OS, Gan’kina OA, Chimagomedova AS, Levikov DI. Autoimmune Anti-NMDA Receptor Encephalitis. Neuroscience and Behavioral Physiology. 2018;48(5):650-656. https://doi.org/10.1007/s11055-018-0612-6
  59. Gozzard P, Woodhall M, Chapman C, Nibber A, Waters P, Vincent A, Lang B, Maddison P. Paraneoplastic neurologic disorders in small cell lung carcinoma. Neurology. 2015;85(3):235-239. https://doi.org/10.1212/wnl.0000000000001721
  60. Afshari M, Afshari ZS, Schuele SU. Pearls & Oy-sters: Hashimoto encephalopathy. Neurology. 2012;78(22):134-137. https://doi.org/10.1212/wnl.0b013e3182582fd4
  61. Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, Honig LS, Benseler SM, Kawachi I, Martinez-Hernandez E, Aguilar E, Gresa-Arribas N, Ryan-Florance N, Torrents A, Saiz A, Rosenfeld MR, Balice-Gordon R, Graus F, Dalmau J. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. The Lancet Neurology. 2013;12(2):157-165. https://doi.org/10.1016/s1474-4422(12)70310-1
  62. Kent L, Amlani A, Vundavalli S, Ridha B, Vera J. Clinical use of brain magnetic resonance imaging for neurological symptoms in people living with HIV. HIV Medicine. 2018;19(7):66-67. https://doi.org/10.1111/hiv.12580
  63. Van der Meulen M, Dirven L, Habets EJJ, van den Bent MJ, Taphoorn MJB, Bromberg JEC. Cognitive functioning and health-related quality of life in patients with newly diagnosed primary CNS lymphoma: a systematic review. The Lancet Oncology. 2018;19(8):407-418. https://doi.org/10.1016/s1470-2045(18)30356-5
  64. Alford K, Vera JH. Cognitive Impairment in people living with HIV in the ART era: A Review. British Medical Bulletin. 2018;127(1):55-68. https://doi.org/10.1093/bmb/ldy019
  65. Wilson MR, Shanbhag NM, Reid MJ, Singhal NS, Gelfand JM, Sample HA, Benkli B, O’Donovan BD, Ali IK, Keating MK, Dunnebacke TH, Wood MD, Bollen A, De Risi JL. Diagnosing Balamuthia mandrillaris Encephalitis with Metagenomic Deep Sequencing. Annals of Neurology. 2015;78(5):722-730. https://doi.org/10.1002/ana.24499
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.